Hosted on MSN53m
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top EstimatesBiotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 ...
For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback